|
|
103 Carnegie Center Drive Suite 300
Princeton, NJ 08540 USA
phone:267-441-4216
fax:
|
|
| Symbol |
Private |
| Founded |
2009 |
| Employees |
6 |
|
|
| www.lltech.fr
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Provides rapid, cellular level, 2D and 3D high resolution imaging systems for real-time, non-destructive optical biopsy readings. |
|
| Management |
| Bertrand Le Conte de Poly, CEO;
Pr. Claude Boccara, CSO: Dean of Research at ESPCI-Paris University;
Mathieu Petitjean, Ph.D. COO;
Peter Lutes, Director of Finance |
| |
|
|
| |
|
| Keywords |
| medical imaging, 2D, 3D, optical biopsy, histopathology, laser-based devices, OCT, photon diagnostics |
|
|
|
| Description |
|
LLTech is a revenue-stage company that sells high-resolution medical imaging systems. The company's products provide a real-time, digital, 3D capable alternative to traditional histopathology. |
|
| Products / Services |
The Light-CT imaging system provides virtual navigation of the analyzed tissue at a cellular level. The system produces rapid 2D and insightful 3D images while preserving the integrity of the sample. As a result, immediate, actionable data is produced in the lab or operating room, while leaving tissue samples in tact for subsequent analysis.
|
|
| Technology / Differentiation |
| LLTech's Light-CT system is safer and smaller than laser-based devices, and offers higher resolution and 3D capability that other traditional OCT and single photon diagnostic tools do not. |
|
| Market / Customers |
The $500 million research market is the first target for LLTech. The company just sold and installed its first Light-CT system at a large pharmaco in the region. Clinical use is the second market - three times larger than the research market. LLTech is coordinating a clinical study at four US and European research hospitals. The study will encompass safety and analysis of breast and dermatologic
|
|
| Status |
| LLTech is selling product in the research market, and is preparing for regulatory approval in Europe and the US. The company is seeking a $7 million series A round to fund operations through early 2013 when it forecasts profitably. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members